The U.S. Senate Finance Committee’s new Democratic chair is considering bringing back a bipartisan bill from the last session of Congress that would require drug manufacturers to pay the federal government rebates on Medicare Part B and Part D drugs for which prices rise faster than the rate of inflation, Political Pro health care reporter Sarah Owermohle told 340B stakeholders on Tuesday during a talk about drug pricing reform.
Owermohle, who covers drug pricing and the COVID-19 pandemic for Politico Pro, was a featured speaker during the 340B Coalition winter conference. Senate Finance Chair Ron Wyden (D-Ore.) wrote the inflation-indexed Medicare rebate bill that Owermohle spoke of with ex-chair Charles Grassley (R-Iowa). Wyden withdrew his support for the bill last July when Grassley reintroduced it, minus the rebates for Part D drugs. Several Senate Republicans opposed including Part D drugs, Owermohle pointed out.
The U.S. Senate Finance Committee’s new Democratic chair is considering bringing back a bipartisan bill from the last session of Congress that would require drug manufacturers to pay the federal government rebates on Medicare Part B and Part D drugs for which prices rise faster than the rate of inflation, Political Pro health care reporter Sarah Owermohle told 340B stakeholders on Tuesday during a talk about drug pricing reform.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
